RecruitingANCA-Associated Glomerulonephritis (AAGN)ANCA-Associated Vasculitis (AAV)
Obinutuzumab Beta Combined With Low-dose Glucocorticoid in New-onset ANCA-Associated Glomerulonephritis
Eligible age
18+ yrs
Accepts
All genders
Locations
0 states
Healthy volunteers
No
See if you qualify for this study
Answer a few quick questions about your location and health. Takes about a minute.
About this study
This study is an open-label, single-arm, exploratory study designed to evaluate the efficacy and safety of Obinutuzumab beta combined with a rapid-tapering glucocorticoid regimen in patients with new-onset ANCA-associated glomerulonephritis (AAGN).
Sponsor: Chinese PLA General Hospital
You may qualify if…
- ✓ New diagnosis of ANCA-associated vasculitis (Granulomatosis with polyangiitis \[GPA\] or Microscopic polyangiitis \[MPA\]) according to the Chapel Hill Consensus Conference definitions.
- ✓ Positive for PR3-ANCA or MPO-ANCA.
- ✓ Active renal involvement indicated by recent renal biopsy (pauci-immune necrotizing and/or crescentic glomerulonephritis) OR active urine sediment characterized by glomerular hematuria and proteinuria.
- ✓ Provided signed informed consent.
You may not qualify if…
- ✕ Prior treatment with targeted B-cell therapies (e.g., Rituximab) or standard cyclophosphamide, azathioprine, or mycophenolate mofetil for AAV.
- ✕ Current requirement for dialysis, or history of dialysis.
- ✕ Presence of life-threatening acute vasculitis manifestations other than renal involvement (e.g., diffuse alveolar hemorrhage, respiratory failure, bowel perforation, cerebral vasculitis).
- ✕ History of malignancy within the past 5 years.
- ✕ Coexisting multisystem autoimmune diseases (e.g., systemic lupus erythematosus, anti-GBM disease).
- ✕ Active severe infections, active tuberculosis, or chronic viral infections (HBV with positive HBsAg or HBV-DNA, active HCV, HIV).
- ✕ Pregnant or lactating women.
Source: ClinicalTrials.gov · NCT07746180 · last updated 2026-09-15